mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice
Stefan Thiem, Thomas P Pierce, Michelle Palmieri, Tracy L Putoczki, Michael Buchert, Adele Preaudet, Ryan O Farid, Chris Love, Bruno Catimel, Zhengdeng Lei, Steve Rozen, Veena Gopalakrishnan, Fred Schaper, Michael Hallek, Alex Boussioutas, Patrick Tan, Andrew Jarnicki, Matthias Ernst
Journal of Clinical Investigation | AMER SOC CLINICAL INVESTIGATION INC | Published : 2013
Awarded by National Health and Medical Research Council Australia (NHMRC)
Awarded by Deutsche Forschungsgemeinschaft
We thank Rachel Hughan, Christine Dijkstra, Elsbeth Richardson, Valarie Feakes, Cary Tsui, and the LICR animal facility staff for expert technical assistance. We thank Stefan Rose-John (Christian-Albrechts-Universitat zu Kiel) for recombinant IL-6 and hyper-IL-6, Lorraine Robb (Walter and Eliza Hall Institute) for recombinant IL-11, and Nick Wilson (CSL Limited, Melbourne, Australia) for providing IL-11R alpha-expressing BaF3 cells. We are grateful to Florian Greten. and Joan Heath for helpful discussions. This work was supported by funds from the Operational Infrastructure Support Program provided by the Victorian Government (Australia) and the following grants from the National Health and Medical Research Council Australia (NHMRC): no. 433617, no. 487922, no. 603122, no. 603132, and no. 1008614. M. Ernst is a Senior Research Fellow of the NHMRC. Work of Michael Hallek was supported by Deutsche Forschungsgemeinschaft SFB 832 (A16). The contents of this material are solely the responsibility of the Administering Institution, Participating Institutions, or individual authors and do not reflect the views of NHMRC.